Neurotensin是一种由13个氨基酸组成的神经肽，具有神经递质、激素和神经调质功能。
Cas No.:39379-15-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Neurotensin is a neuropeptide composed of 13 amino acids, which functions as a neurotransmitter, hormone, and neuromodulator. Neurotensin lowers blood pressure, inhibits gastrointestinal motility and gastric acid secretion to regulate digestive function, while also modulating ceramide synthesis via the NTS-NTSR2 signaling pathway to reduce inflammation and regulate metabolism. Neurotensin can be used in research related to neuropsychiatric disorders (such as schizophrenia and Parkinson's disease) and metabolic diseases (such as obesity and metabolic-associated fatty liver disease)[1-4].
In vitro, Neurotensin (1μM) treated MKN-1 and MKN-45 gastric cancer cells for 5 minutes. Neurotensin activated the expression and activity of matrix metalloproteinase-9 (MMP-9) through the NTR1 receptor, promoting cell invasion and migration[5]. Neurotensin (0.1μM) treated Calu-3, NCI-H358, and NCI-H441 non-small cell lung cancer cells for 5 minutes. Neurotensin significantly increased HER3 tyrosine phosphorylation and promoted the formation of EGFR/HER3 and HER2/HER3 heterodimers[6].
In vivo, Neurotensin (1pg–25ng; single injection) was administered intracerebroventricularly to CD-1 mice. Neurotensin significantly antagonized the analgesic effect induced by morphine[7]. Neurotensin (10μg; single injection) was administered intrathecally to C57BL/6 mice. Neurotensin significantly alleviated thermal pain and formaldehyde-induced pain[8].
References:
[1] Staley J, Fiskum G, Davis TP, et al. Neurotensin elevates cytosolic calcium in small cell lung cancer cells. Peptides. 1989 Nov-Dec;10(6):1217-21.
[2] Ehlers RA, Zhang Y, Hellmich MR, et al. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun. 2000 Mar 24;269(3):704-8.
[3] Okamoto A, Nakanishi T, Tonai S, et al. Neurotensin induces sustainable activation of the ErbB-ERK1/2 pathway, which is required for developmental competence of oocytes in mice. Reprod Med Biol. 2024 Mar 20;23(1):e12571.
[4] Banerjee M, Song J, Yan B, et al. Neurotensin promotes hepatic steatosis by regulating lipid uptake and mitochondrial adaptation in hepatocytes. Cell Death Dis. 2025 Apr 27;16(1):347.
[5] Akter H, Park M, Kwon OS, et al. Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol. 2015 Aug;36(8):6053-62.
[6] Moody TW, Ramos-Alvarez I, Jensen RT. Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3. Peptides. 2022 Oct;156:170858.
[7] Holmes BB, Rady JJ, Smith DJ, et al. Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin. Jpn J Pharmacol. 1999 Feb;79(2):141-9.
[8] Barnwal A, Tamang R, Sanjeev Das, et al. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression. Br J Cancer. 2023 Oct;129(6):1007-1021.
Neurotensin是一种由13个氨基酸组成的神经肽，具有神经递质、激素和神经调质功能。Neurotensin可降低血压、抑制胃肠运动及胃酸分泌来调节消化功能，同时通过NTS-NTSR2信号通路调控神经酰胺合成以减少炎症和调节代谢。Neurotensin可用于神经精神疾病（如精神分裂症、帕金森病）和代谢疾病（如肥胖、代谢相关脂肪肝）的相关研究[1-4]。
在体外，Neurotensin（1μM）处理MKN-1和MKN-45胃癌细胞5分钟。Neurotensin通过NTR1受体激活基质金属蛋白酶-9（MMP-9）的表达和活性，促进细胞侵袭和迁移[5]。Neurotensin（0.1μM）处理Calu-3、NCI-H358和NCI-H441非小细胞肺癌细胞5分钟。Neurotensin显著增加HER3酪氨酸磷酸化，同时促进EGFR/HER3和HER2/HER3异源二聚体形成[6]。
在体内，Neurotensin（1pg-25ng；单次注射）侧脑室注射于CD-1小鼠。Neurotensin显著拮抗了吗啡诱导的镇痛作用[7]。Neurotensin（10μg；单次注射）鞘内注射于C57BL/6小鼠。Neurotensin显著减轻了热痛和福尔马林诱导的疼痛[8]。
| Cell experiment [1]: | |
Cell lines | Calu-3, NCI-H358, and NCI-H441 cells (non-small cell lung cancer cell lines) |
Preparation Method | Cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS). When confluent, cells were washed with SIT medium (RPMI-1640 containing sodium selenite, bovine insulin and apo-transferrin) for 2 hours. Cells were treated with inhibitors (e.g., SR48692, mAb3481, PP2, GM6001, PD98059, LY294002, N-acetylcysteine or Tiron) for 30min. Then Neurotensin (0.1μM) or Neuregulin 1 (NRG1) was added. |
Reaction Conditions | 0.1μM; 5min |
Applications | Neurotensin significantly increased tyrosine phosphorylation of HER3 in NSCLC cells. NTS addition to NCI-H441 cells resulted in the formation of EGFR/HER3 and HER2/HER3 heterodimers. Adding Neurotensin to NSCLC cells increased phosphorylation of ERK, HER3, and AKT. Neurotensin increased colony formation of NSCLC cells. The ability of Neurotensin to increase HER3 tyrosine phosphorylation was impaired by SR48692 (NTSR1 antagonist), monoclonal antibody 3481 (HER3 blocker), GM6001 (MMP inhibitor), PP2 (Src inhibitor), Tiron (superoxide scavenger), or N-acetylcysteine (antioxidant). |
| Animal experiment [2]: | |
Animal models | Male CD-1 mice (weighing 25 to 30g) |
Preparation Method | Mice were administered Neurotensin (1pg to 25ng) intracerebroventricularly (i.c.v.) in a volume of 4μl under light halothane anesthesia, generally 10min before the tail flick test (TFT). Morphine was administered intrathecally (i.t.) 5min before the TFT. |
Dosage form | 1pg to 25ng; i.c.v.; single injection |
Applications | Neurotensin significantly antagonized the antinociceptive (analgesic) action of morphine administered intrathecally. This antianalgesic action of Neurotensin was mediated by spinal cholecystokinin (CCK). |
References: | |
| Cas No. | 39379-15-2 | SDF | |
| 别名 | 神经降压素 | ||
| 化学名 | (Z)-5-(((Z)-1-((6-amino-1-(2-((Z)-(((Z)-1-((1-(2-((Z)-(((Z)-1-(((Z)-1-((1-carboxy-3-methylbutyl)imino)-1-hydroxy-3-methylpentan-2-yl)imino)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)imino)(hydroxy)methyl)pyrrolidin-1-yl)-5-guanidino-1-oxopentan-2-yl)imino) | ||
| Canonical SMILES | CCC(C(/N=C(O)/C(/N=C(O)/C1CCCN1C(C(/N=C(O)/C(/N=C(O)/C2CCCN2C(C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C3CCC(O)=N3)CC(C)C)CC4=CC=C(O)C=C4)CCC(O)=O)CC(O)=N)CCCCN)=O)CCCNC(N)=N)CCCNC(N)=N)=O)CC5=CC=C(O)C=C5)/C(O)=N/C(C(O)=O)CC(C)C)C | ||
| 分子式 | C78H121N21O20 | 分子量 | 1672.94 |
| 溶解度 | Soluble to 0.70 mg/ml in sterile water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 597.8 μL | 2.9888 mL | 5.9775 mL |
| 5 mM | 119.6 μL | 597.8 μL | 1.1955 mL |
| 10 mM | 59.8 μL | 298.9 μL | 597.8 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet